GRAIL, Inc. (GRAL) Q3 2026 earnings results
GRAIL, Inc. (GRAL) reported Q3 2026 results on Nov 4, 2026, 4:05:32 PM ET: GAAP EPS -$2.21 vs. -$1.90 expected (miss by 16.4%); revenue $37.53M vs. $44.21M expected (miss by 15.1%). Outlook: The company anticipates an FDA decision by early Q1 2027.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$2.21 | -$1.90 | Miss by 16.4% |
| Revenue | $37.53M | $44.21M | Miss by 15.1% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 4, 2026, 4:05:32 PM ET. Nexqual published them 59 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 3.7% from $36.19M; GAAP diluted EPS was -$2.21 vs. -$2.46 (+10.2%).
Stock reaction
The results came out after the market closed. GRAL closed at $119.13 on November 5, 2026, down 17.1% from its $143.66 close on November 4, 2026 before the results. Latest: $123.02 as of 11:46 AM ET, −14.4% since the pre-release close.
Questions and answers
Did GRAIL, Inc. beat earnings expectations?
No. GRAIL, Inc. reported GAAP EPS of -$2.21 against an average analyst estimate of -$1.90 (miss by 16.4%), and revenue of $37.53M against $44.21M expected (miss by 15.1%).
What were GRAIL, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of -$2.21 and revenue of $37.53M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 3.7% from $36.19M; GAAP diluted EPS was -$2.21 vs. -$2.46 (+10.2%).
When did GRAIL, Inc. report Q3 2026 earnings?
Nov 4, 2026, 4:05:32 PM ET, in an SEC 8-K filing (Item 2.02).
How did GRAL stock react to the earnings?
The results came out after the market closed. GRAL closed at $119.13 on November 5, 2026, down 17.1% from its $143.66 close on November 4, 2026 before the results. Latest: $123.02 as of 11:46 AM ET, −14.4% since the pre-release close.
What did GRAIL, Inc. say about its outlook?
The company anticipates an FDA decision by early Q1 2027.
More on GRAL
GRAL stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 4, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:46 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:46 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt